GLP-1 and Liver Enzymes (ALT, AST, GGT): What Changes

If your ALT or AST moved after starting Ozempic, Wegovy, Mounjaro, or Zepbound, the most likely direction is down, not up. GLP-1 (and GLP-1/GIP) drugs reduce liver fat, and as the fat clears, the leaked liver enzymes (ALT, AST, and often GGT) typically fall. This is so well-established that in 2025 the FDA approved semaglutide 2.4 mg (Wegovy) to treat the serious liver disease MASH, on the strength of the phase 3 ESSENCE trial (Sanyal 2025 ^[5]). The foundational liver-enzyme data go back to the liraglutide LEAD program (Armstrong 2013 ^[1]), and multiple meta-analyses confirm GLP-1 therapy lowers ALT and liver-fat fraction (Carbone 2016 ^[2]; Bandyopadhyay 2023 ^[3]; Zou 2023 ^[4]). The rare exception — genuine drug-induced liver injury — does exist but is uncommon, and is the opposite pattern (a sharp rise with symptoms). This article explains what your numbers are actually telling you. For the kidney equivalent, see the early eGFR dip on a GLP-1.

The honest summary

• GLP-1s usually LOWER liver enzymes. Because they reduce hepatic fat, ALT and AST (and frequently GGT) tend to fall over weeks to months. A modest decrease is the expected, favorable pattern.
• The reason is liver-fat reduction, not liver toxicity. Elevated ALT/AST in most people with obesity reflects metabolic-dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). Losing liver fat is what drives the enzymes down.
• Semaglutide is now an FDA-approved MASH treatment. ESSENCE (Sanyal 2025^[5]) showed semaglutide 2.4 mg significantly improved MASH resolution and liver fibrosis versus placebo — the first GLP-1 with an FDA-approved liver indication — and AASLD has issued practice guidance on its use (Bansal 2026^[6]).
• Meta-analyses agree across the class. Armstrong 2013^[1] (liraglutide LEAD), Carbone 2016^[2], Bandyopadhyay 2023^[3] (semaglutide), and Zou 2023^[4] (network meta-analysis) all report reductions in ALT and/or liver-fat fraction.
• A genuine rise is different and uncommon. True drug-induced liver injury (a sharp ALT/AST climb, often with nausea, jaundice, dark urine, or right-upper-quadrant pain) is rare with GLP-1s. That pattern warrants prompt evaluation — it is not the gradual decline most people see.

Why the enzymes usually fall

ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are enzymes that live inside liver cells; they show up in the blood when liver cells are stressed or leaky. In people with obesity or type 2 diabetes, the most common reason for a mildly elevated ALT/AST is fat accumulation in the liver — MASLD (metabolic-dysfunction-associated steatotic liver disease), and its inflammatory form MASH (steatohepatitis). GLP-1 drugs drive weight loss and reduce intrahepatic fat, which relieves that low-grade injury. As the fat content drops, the enzyme leak slows and the numbers normalize. GGT (gamma-glutamyl transferase), often elevated alongside fatty liver and metabolic syndrome, commonly improves in parallel.

Armstrong 2013^[1] — an individual-patient-data meta-analysis of the liraglutide LEAD program in type 2 diabetes with elevated liver enzymes — was an early, rigorous signal that GLP-1 therapy lowers ALT, and that the effect tracked with weight and glycemic improvement. Carbone 2016^[2] extended this across incretin therapies for NAFLD. Bandyopadhyay 2023^[3] focused on semaglutide and NAFLD/NASH, and Zou 2023^[4] ran a network meta-analysis comparing diabetes drugs head-to-head on liver enzymes and MRI-measured fat fraction — with GLP-1 agents among the strongest performers.

ESSENCE: from lowering a lab value to treating the disease

The landmark is ESSENCE (Sanyal 2025^[5], New England Journal of Medicine) — a phase 3 randomized trial of semaglutide 2.4 mg in biopsy-confirmed MASH with moderate-to-advanced fibrosis. Semaglutide met both co-primary histologic endpoints: significantly more patients achieved MASH resolution without worsening of fibrosis, and significantly more achieved fibrosis improvement without worsening of MASH, versus placebo. On that basis the FDA approved Wegovy for MASH in 2025 — the first GLP-1 receptor agonist to carry an FDA-approved liver indication — and the AASLD issued practice guidance on integrating it into MASH care (Bansal 2026^[6]). In other words, the same mechanism that nudges your routine ALT downward is potent enough, at the 2.4 mg dose over time, to reverse liver inflammation and fibrosis on biopsy.

When a change in liver enzymes IS a concern

The reassuring story has one important exception. Genuine drug-induced liver injury (DILI) — a true hepatotoxic reaction — is uncommon with GLP-1 drugs themselves, but it can happen, and the pattern is different from the gradual MASLD-related decline. Red-flag features include a rapid, large rise in ALT/AST (often many times the upper limit of normal), especially with symptoms: new nausea or vomiting that won't settle, loss of appetite, right-upper-abdominal pain, yellowing of the skin or eyes (jaundice), dark urine, or pale stools. A more common real-world scenario is that something else you started at the same time (a supplement, a new prescription, alcohol) is the culprit — supplement-induced liver injury in particular is frequently missed because patients don't mention supplements. Any unexplained sharp rise, or any of those symptoms, should be evaluated promptly rather than waited out.

What to do with your numbers

• A mild downward trend: expected and favorable — your liver fat is likely improving. No action beyond your usual follow-up.
• Stable, mildly elevated: common in early MASLD; your clinician may track it and assess fibrosis (e.g., FIB-4, elastography).
• A new sharp rise, or any red-flag symptom: contact your clinician — review all medications and supplements, and don't assume the GLP-1 is the cause without evaluation.
• Pre-existing liver disease: GLP-1s are generally used (and semaglutide is now indicated in MASH), but advanced cirrhosis and decompensated liver disease need specialist guidance — this is not a self-managed situation.

Bottom line

For the large majority of people, a GLP-1 drug improves liver enzymes by clearing liver fat — and at the 2.4 mg semaglutide dose the effect is strong enough to be an FDA-approved MASH therapy^[5][6]. A gradual fall in ALT/AST/GGT is the expected, healthy pattern^[1][3]. The exception to watch for is the opposite: a rapid rise with symptoms, which is uncommon and deserves prompt evaluation rather than reassurance.

This article is educational and is not medical advice. Every claim above is sourced to a peer-reviewed meta-analysis, phase 3 trial, or society guidance indexed in PubMed, verified against the live PubMed database before publication. Interpret lab results with your own clinician, who has your full history.